Recent News

• 03.18.2026 - Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline
• 03.16.2026 - New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
• 01.09.2026 - Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization
• 11.09.2025 - New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

Recent Filings

• 03.02.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 02.25.2026 - EX-99.1 EX-99.1
• 02.25.2026 - 8-K Current report
• 02.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.08.2026 - 8-K Current report
• 01.08.2026 - EX-99.1 EX-99.1